142 related articles for article (PubMed ID: 15868383)
1. Phase II trial of dolastatin-10 in patients with advanced breast cancer.
Perez EA; Hillman DW; Fishkin PA; Krook JE; Tan WW; Kuriakose PA; Alberts SR; Dakhil SR
Invest New Drugs; 2005 Jun; 23(3):257-61. PubMed ID: 15868383
[TBL] [Abstract][Full Text] [Related]
2. Dolastatin-10 in metastatic melanoma: a phase II and pharmokinetic trial of the California Cancer Consortium.
Margolin K; Longmate J; Synold TW; Gandara DR; Weber J; Gonzalez R; Johansen MJ; Newman R; Baratta T; Doroshow JH
Invest New Drugs; 2001; 19(4):335-40. PubMed ID: 11561695
[TBL] [Abstract][Full Text] [Related]
3. Phase I study of TZT-1027, a novel synthetic dolastatin 10 derivative and inhibitor of tubulin polymerization, which was administered to patients with advanced solid tumors on days 1 and 8 in 3-week courses.
Tamura K; Nakagawa K; Kurata T; Satoh T; Nogami T; Takeda K; Mitsuoka S; Yoshimura N; Kudoh S; Negoro S; Fukuoka M
Cancer Chemother Pharmacol; 2007 Jul; 60(2):285-93. PubMed ID: 17136542
[TBL] [Abstract][Full Text] [Related]
4. Phase I and pharmacokinetic study of TZT-1027, a novel synthetic dolastatin 10 derivative, administered as a 1-hour intravenous infusion every 3 weeks in patients with advanced refractory cancer.
Schöffski P; Thate B; Beutel G; Bolte O; Otto D; Hofmann M; Ganser A; Jenner A; Cheverton P; Wanders J; Oguma T; Atsumi R; Satomi M
Ann Oncol; 2004 Apr; 15(4):671-9. PubMed ID: 15033678
[TBL] [Abstract][Full Text] [Related]
5. Phase II study of LU 103793 (dolastatin analogue) in patients with metastatic breast cancer.
Kerbrat P; Dieras V; Pavlidis N; Ravaud A; Wanders J; Fumoleau P;
Eur J Cancer; 2003 Feb; 39(3):317-20. PubMed ID: 12565983
[TBL] [Abstract][Full Text] [Related]
6. Phase II trials of dolastatin-10 in advanced pancreaticobiliary cancers.
Kindler HL; Tothy PK; Wolff R; McCormack RA; Abbruzzese JL; Mani S; Wade-Oliver KT; Vokes EE
Invest New Drugs; 2005 Oct; 23(5):489-93. PubMed ID: 16133801
[TBL] [Abstract][Full Text] [Related]
7. Phase I trial of dolastatin-10 (NSC 376128) in patients with advanced solid tumors.
Pitot HC; McElroy EA; Reid JM; Windebank AJ; Sloan JA; Erlichman C; Bagniewski PG; Walker DL; Rubin J; Goldberg RM; Adjei AA; Ames MM
Clin Cancer Res; 1999 Mar; 5(3):525-31. PubMed ID: 10100703
[TBL] [Abstract][Full Text] [Related]
8. Phase II study of intravenous TZT-1027 in patients with advanced or metastatic soft-tissue sarcomas with prior exposure to anthracycline-based chemotherapy.
Patel S; Keohan ML; Saif MW; Rushing D; Baez L; Feit K; DeJager R; Anderson S
Cancer; 2006 Dec; 107(12):2881-7. PubMed ID: 17109446
[TBL] [Abstract][Full Text] [Related]
9. Phase II study of dolastatin-10 in patients with hormone-refractory metastatic prostate adenocarcinoma.
Vaishampayan U; Glode M; Du W; Kraft A; Hudes G; Wright J; Hussain M
Clin Cancer Res; 2000 Nov; 6(11):4205-8. PubMed ID: 11106233
[TBL] [Abstract][Full Text] [Related]
10. Phase II study of dolastatin-10 as first-line treatment for advanced colorectal cancer.
Saad ED; Kraut EH; Hoff PM; Moore DF; Jones D; Pazdur R; Abbruzzese JL
Am J Clin Oncol; 2002 Oct; 25(5):451-3. PubMed ID: 12393982
[TBL] [Abstract][Full Text] [Related]
11. A phase II trial of dolastatin-10 in recurrent platinum-sensitive ovarian carcinoma: a Gynecologic Oncology Group study.
Hoffman MA; Blessing JA; Lentz SS;
Gynecol Oncol; 2003 Apr; 89(1):95-8. PubMed ID: 12694660
[TBL] [Abstract][Full Text] [Related]
12. A phase I study of the dolastatin-15 analogue tasidotin (ILX651) administered intravenously daily for 5 consecutive days every 3 weeks in patients with advanced solid tumors.
Ebbinghaus S; Rubin E; Hersh E; Cranmer LD; Bonate PL; Fram RJ; Jekunen A; Weitman S; Hammond LA
Clin Cancer Res; 2005 Nov; 11(21):7807-16. PubMed ID: 16278403
[TBL] [Abstract][Full Text] [Related]
13. Paclitaxel combined with weekly high-dose 5-fluorouracil/folinic acid and cisplatin in the treatment of advanced breast cancer.
Klaassen U; Wilke H; Seeber S
Semin Oncol; 1996 Oct; 23(5 Suppl 11):32-7. PubMed ID: 8893897
[TBL] [Abstract][Full Text] [Related]
14. Multitargeted antifolate LY231514 as first-line chemotherapy for patients with advanced non-small-cell lung cancer: A phase II study. National Cancer Institute of Canada Clinical Trials Group.
Rusthoven JJ; Eisenhauer E; Butts C; Gregg R; Dancey J; Fisher B; Iglesias J
J Clin Oncol; 1999 Apr; 17(4):1194. PubMed ID: 10561178
[TBL] [Abstract][Full Text] [Related]
15. Docetaxel-ifosfamide combination in patients with advanced breast cancer failing prior anthracycline-based regimens: results of a phase I-II study.
Kosmas C; Tsavaris N; Mylonakis N; Tsakonas G; Gassiamis A; Skopelitis H; Polyzos A; Malamos N; Karabelis A
J Chemother; 2007 Jun; 19(3):322-31. PubMed ID: 17594929
[TBL] [Abstract][Full Text] [Related]
16. Activity of the dolastatin analogue, LU103793, in malignant melanoma.
Smyth J; Boneterre ME; Schellens J; Calvert H; Greim G; Wanders J; Hanauske A;
Ann Oncol; 2001 Apr; 12(4):509-11. PubMed ID: 11398885
[TBL] [Abstract][Full Text] [Related]
17. A phase II study of the dolastatin 15 analogue LU 103793 in the treatment of advanced non-small-cell lung cancer.
Marks RS; Graham DL; Sloan JA; Hillman S; Fishkoff S; Krook JE; Okuno SH; Mailliard JA; Fitch TR; Addo F
Am J Clin Oncol; 2003 Aug; 26(4):336-7. PubMed ID: 12902880
[TBL] [Abstract][Full Text] [Related]
18. Phase II trial of N,N-diethyl-2-[4-(phenylmethyl)phenoxy]ethanamine.HCl and doxorubicin chemotherapy in metastatic breast cancer: A National Cancer Institute of Canada clinical trials group study.
Khoo K; Brandes L; Reyno L; Arnold A; Dent S; Vandenberg T; Lebwohl D; Fisher B; Eisenhauer E
J Clin Oncol; 1999 Nov; 17(11):3431-7. PubMed ID: 10550138
[TBL] [Abstract][Full Text] [Related]
19. Pemetrexed in patients with locally advanced or metastatic breast cancer who had received previous anthracycline and taxane treatment: phase II study.
Llombart-Cussac A; Theodoulou M; Rowland K; Clark RS; Nakamura T; Carrasco E; Cruciani G
Clin Breast Cancer; 2006 Dec; 7(5):380-5. PubMed ID: 17239262
[TBL] [Abstract][Full Text] [Related]
20. Phase I studies of combined paclitaxel/epirubicin and paclitaxel/epirubicin/cyclophosphamide in patients with metastatic offast cancer: the French experience.
Catimel G; Spielmann M; Dieras V; Tubiana-Hulin M; Bonneterre J; Pouillart P; Kayitalire L; Guastalla JP; Graffand N; Garet F; Dumortier A; Pellae-Cosset B
Semin Oncol; 1997 Feb; 24(1 Suppl 3):S8-12. PubMed ID: 9071333
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
